StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) stock

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3057% below fair value
$3.34+0.13 (+4.05%)

Close on Nov 19, 2026Market cap $104.94MP/E –Yield –

LENZ Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

LENZ Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$114.42M. For fiscal 2025 it was -$70.00M. The highest annual figure on record is -$10.27M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$70.00M–
FY2024Dec 31, 2024-$59.86M–
FY2023Dec 31, 2023-$60.41M–
FY2022Dec 31, 2022-$94.57M–
FY2021Dec 31, 2021-$58.59M–
FY2020Dec 31, 2020-$10.27M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$38.73M–
Q1 FY2026Mar 31, 2026-$33.60M–
Q4 FY2025Dec 31, 2025-$33.06M–
Q3 FY2025Sep 30, 2025-$9.03M–
Q2 FY2025Jun 30, 2025-$11.75M–
Q1 FY2025Mar 31, 2025-$16.16M–
Q4 FY2024Dec 31, 2024-$9.23M–
Q3 FY2024Sep 30, 2024-$10.77M–
Q2 FY2024Jun 30, 2024-$15.93M–
Q1 FY2024Mar 31, 2024-$23.94M–
Q4 FY2023Dec 31, 2023-$20.97M–
Q3 FY2023Sep 30, 2023-$13.09M–
Q2 FY2023Jun 30, 2023-$13.55M–
Q1 FY2023Mar 31, 2023-$12.80M–
Q4 FY2022Dec 31, 2022-$23.45M–
Q3 FY2022Sep 30, 2022-$23.13M–
Q2 FY2022Jun 30, 2022-$23.48M–
Q1 FY2022Mar 31, 2022-$24.51M–
Q4 FY2021Dec 31, 2021-$16.57M–
Q3 FY2021Sep 30, 2021-$19.05M–
Q2 FY2021Jun 30, 2021-$14.55M–
Q1 FY2021Mar 31, 2021-$8.42M–
Q4 FY2020Dec 31, 2020-$5.88M–
Q3 FY2020Sep 30, 2020-$3.05M–

More LENZ Therapeutics figures

See a number that looks wrong?